under identical conditions failed to yield these immunologically active products, suggesting that the results obtained with iodine-125 are in part due to a radiolytic reaction not observed with the iodine-127. In an attempt to characterize these iodination products chemically and immunologically, we iodinated morphine and dihydromorphine with use of nonradioactive Na'271. The immunologically active products found after iodination with Na'25I were absent after iodination with Na1271. These findings strongly suggest that the immunologically active products formed during the radioiodination of morphine and dihydromorphine are the result of a radiochemical or radiolytic reaction.
The results reported herein support this hypothesis.
Materials and Methods

lodination of Morphine and Dihydromorphine
Fifty microliters (0.17 zmol) of a 1 mg/ml solution of morphine sulfate in distilled water or dihydromorphine in equal volumes of acetone and water, was added to a vial containing 5 mCi (2.3 nmol) of carrier-free 1251 (Amersham/Searle Corp., Arlington Heights, Ill. 60005). After mixing, we added 40 il of Chloramine-T (sodium p -toluene sulfonchloramide, 5 mg/ml) in sodium borate buffer (50 mmol/liter, pH 8.4). The resulting reaction mixture was agitatedfor 1.5 mm and then 40 il of sodium metabisulfite (10 mg/ml) in sodium borate buffer was added to stop the reaction,
The mixture was then transferred to a 1.5 X 90 cm column filled with Bio-Gel P-2 (Bio-Rad Laboratories, Richmond, Calif. 94804) to which 1.0 ml of normal human plasma had been added. The vial was then rinsed with 200 il of normal human plasma and the washings transferred to the column. Before the radioactive sample was added, the column had been coated with normal human plasma and then washed with about 400 ml of 0.1 mol/liter tris(hydroxytnethyl)aininomethane HC1 buffer, pH 7.0, containing 20 mg of NaN3 and 0.9 g of NaC1 per deciliter. The reaction mixture in normal human plasma was allowed to penetrate the column, followed by 2 ml of tris(hydroxymethyl)aminomethane HC1 bufferwash. The same buffer was used as eluent; 5.0-ml fractions were collected in a fraction collector.
Aliquots, 25 gil, from each fraction were counted in a gamma scintillation counter and the resulting elution pattern was graphed.
The amounts of reactants used in our attempts to iodinate morphine or dihydromorphine with nonradioactive iodine were increased 20-fold, to provide enough product for chemical characterization. Thus, 1.0 ml of the same 1 mg/ml solution of morphine sulfate used in iodine-125 iodinations was added to 1 ml of Na127I (5 sg/ml; pH adjusted to 8-11 with NaOH, as in the Amersham/Searle Na125I product), followed by 0.8 ml of Chloramine-T (5 mg/ml in the borate buffer) and Na2S2O5 (10 mg/ml, in the borate buffer) according to the iodination procedure described above. The reaction mixture was fractionated in the same manner and on the same Bio-Gel P-2 column [pre-washed with Na1271 and tris(hydroxymethyl)- 0.5 ml of saturated (NH4)2S04 was added to all tubes after the 1-h incubation.
The rest of the assay was done as described for the antigenbinding assay. We used a calibration curve based on triplicate determinations of standard morphine solutions containing 0, 10, 20, 40, and 80 ,g/liter.
Assay by isotope Dilution
The assay used to detect the peaks corresponding to morphine and 1271-labeled morphine depended on the ability of these compounds to compete with 3H-I'abeled morphine for antibody binding sites. It was therefore necessary to show that '271-labeled morphine was not detected in our column eluates simply because of a difference in the reactivity with antibody of 1271-labeled morphine and 3H-labeled morphine. Because these compounds would be expected to compete equally for antibody binding sites, assay by isotope dilution was invoked.
In this procedure, 0.1-mi aliquots of fractions collected after labeling morphine with Na'271 were added to 12 X 75 mm tubes containing 0.1 ml of normal human serum and 0.1 ml of antimorphine serum.
A constantamount In addition, any difference in elu. tion patterns between morphine and '271-labeled morphine could be determined by using essentially the same assay as that used to detect peaks for 125I labeled morphine.
Thin-layer chromatography
To distinguish iodination reaction products from each other and from initial reactants, we used the thin-layer chromatographic methods outlined by Fike (4), with silica gel plates, impregnated with 0.1 mol/liter KOH, and with methanol as the developing solvent.
Iodine vapor was used to detect unlabeled morphine.
To determine the extent of migration of radioactive samples, we removed 1-cm sections of the silica gel, eluted with physiological saline, and the radioactivity in the eluates was counted in the gamma scintillation counter. Only one peak with morphine displacement activity was seen, between fractions 36-42. This antigenic peak corresponded to the second radioactive peak in Figure 1 . After a second morphine iodination with Na1271 each fraction was assayed by the isotope dilution assay to determine the capacity of the '271-labeled morphine to displace 125I-labeled morphine from antibody. These results (Figure 2) show clearly that the morphine detected in fractions 36 to 42 of the previous experiment was capable of competing with the '25I-labeled morphine for antibody binding sites. In addition, a small peak was seen in fractions 45-48.
In neither of these experiments was a peak found that corresponded to the third radioactive peak observed after iodination with Na1251. lodination of dihydromorphine with Na1251. Figure 3 shows a typical elution curve obtained after iodination of dihydromorphine (1 mg/ml in equal volumes of acetone and water) with Na'251. Comparing this plot with that for '25I-labeled morphine ( Figure  1) , it can be seen that the antibody binding peak was eluted 30 ml (six fractions) after the major radioactive peak rather than 65 ml (13 fractions) later, as in the 1251-labeled morphine curve. In addition, the small radioactive peak in fractions 20-34 ofthe curve for '251-labeled morphine, was consistently absent from '251-labeled dihydromorphine curves. A standard Na'251 iodinationreactionwas done in the absence of morphine and normal human plasma. A single radioactive peak was eluted ( Figure  6 ) in about the same volume of buffer required to elute the second radioactive peak seen when morphine was included in the reaction mixture ( Figure  1) .
Oxidation
of morphine sulfate in the absence of iodide. To further assess the importance of radioactivity to production of a morphine peak with antibody binding capacity, we treated morphine sulfate with the usual amounts of Chloramine-T (5 mg/mi) and Na2S2O5 (10 mg/mi) in the absence of iodide.
After chromatography on Bio-Gel P-2, with normal human plasma omitted, 3H-morphine displacement activitywas determined. Because the major morphine peak occurredat tube 43 (Figure 6 ), it is likely that unlabeled morphine is the major constituent of the peak characteristically isolated after iodination with Na'27!.
Effect of decreasing the ratio of morphine to iodide. In the previous experiments, the molar ratio of morphine to Na'25! or Na'271 used in the iodination reaction was about 70. When equimolar amounts of morphine, Chloramine-T, and Na1251 were used in the labeling procedure, the major peak of radioactivity was found at tube 41 while counts amounting to only about four times background were obtained in The usualIodlnatlon procedure was foowed for both experiments except that Na'251was omitted In one case, morphine In the other tubes 46-53. About 45% of the latter materialdid, however, bind to morphine antibody.
Thin-layer chromatography.
The radioactive fractions composing peaks 2 and 3, separated on Bio-Gel P-2 columns after 125I-labeling ( Figure 5 ), were pooled separately and assayed by thin-layer chromatography along with morphine sulfate and Na'25I. The Rp value (distance peak migrated/distance to solvent front) of 0.25 obtained for unlabeled morphine, agrees well with the value of 0.28 reported by Fike (4). R' values calculated for peaks 2 and 3 (Figure 5) were 0.80 and 0.75, respectively, while the Na125! migrated slightly faster(RF = 0.87). Several TLC experiments in which peaks 2 and 3 were. compared with Na'25! before and after treatment of the latter with Chloramine-T and Na2S2O5 failed to unequivocally distinguish these compounds from Na'25I.
In efforts to correlate radioactivity with antigen bindingactivity, we assayed extracts of silica gelsections,suspended in 0.14 mol/literNaC1 or tris(hydroxymethyl)aminomethane HC1 buffer, for 125!.. morphine bindingto antibody.Although at least80% ofthe radioactivity was elutedfrom the silica gelsections, no antibody binding activitywas recovered, These results indicate either that 1251 was separated from the labeled immunologicallyactive hapten during elutionfrom silica gel or that haptenic activity was destroyed.
DEAE-cellulose chromatography.
Fractions 54 through 56 (Figure5)-those containingthe '251-la- beled morphine with the highest binding activity to antibody-were pooled and, after storage at 4 #{176}C for one month, chromatographed on a DEAE-cellulose column. As shown in Figure 7A , two radioactive peaks were observed, the major peak, composed of fractions 9-12 contained most of the antibody activity, and a small peak at fractions 19-23 that failed to bind significantly toantibody. Fractions10-11 from the DEAE-cellulose column were pooled and rechromatographed on the same DEAE-cellulose column. The column had been thoroughly washed and re-equilibrated with the tris(hydroxymethyl)aminomethane HC1 buffer. A linear salt gradient identical to that used for previous elution from the column was used. Two peaks ( Figure 7B) of radioactivity, at fractions 9-12 and 20-25, were again obtained, with virtually all the binding of antigen to antibody being associated with the first peak. Fractions 9-12 from this column were then pooled and stored at 4 #{176}C for two weeks. The pooled material was again chromatographed on the DEAE-column under the same conditions as before; again, two peaks of radioactivity were observed ( Figure 7C ), at fractions 9-12 and 22-28. The second peak comprised 6% of the total radioactivity and none of the antimorphine binding activity.
Stability and Immunologic Reactivity of 1251-Iabeled Morphine
The data obtained by thin-layer and DEAE-cellulose chromatography suggested a steady dissociation of the 125I-label from morphine.
Such a dissociation could profoundly affect both the stability and immunological reactivity of the antigen. Therefore the following stability experiment was done: '251-labeled morphine reagent and the corresponding matched antibody reagent were prepared as described above under Radioimmunoassay for Morphine Detection.
The two reagents were storedseparatelyat 4 #{176} C for 33 days and then kept at 45 #{176}C, 37 #{176}C, 26 #{176}C, and 4 #{176}C, either as separate reagents or in the premixed ing. For each test, morphine standards (0, 10, 20, 40, and 80 ig of morphine per liter of urine) were assayed in triplicate and the average cpm in the supernates was calculated. To eliminate the variable of radioactivity decay the percentage of free 1251-labeled morphine in the supernate for each morphine standard was calculated in relation to that free when no unlabeled morphine was present. Figure 8 shows the results obtained after incubation of the reagents at 4, 25, and 37 #{176}C. When the reagents were stored at 4#{176}C, whether separately or premixed, no noticeable change in the slopes of the curves was observed even after eight weeks of storage ( Figure 8A ). Not shown is the curve when the reagents were initially prepared. The latter curve was essentially the same as that seen for the reagents stored at 4 #{176}C, indicating the '251-labeled morphine antigen was immunologically stable even after 89 days at 4 #{176}C. When the reagents were incubated at 37 #{176}C in the premix form, as shown in Figure 8B , we saw no change in the slopes of the curves. However, at this elevated temperature, storage of the reagents separately resulted in a marked flattening of the curves with increasing time of storage ( Figure 8C ). At 25 #{176}C, the curves with the premix reagents were the same as those observed at 4 #{176}C and 37 #{176}C ( Figure 8D ). The flattening trend observed when the reagents were stored separately at 37 #{176}C was also evident at room temperature, but not as marked. Storage at 45 #{176}C for one week did not alter the slope of the curve of premixed reagents, but resulted in a slope similar to that seen at 2 weeks when the reagents were stored separately at 37 #{176}C.
Degradation of 125i-labeied Morphine Antigen
To determine whether the antibody or 1251-labeled morphine (or both), stored separately at temperatures above 4 #{176}C, were unstable, we did the following experiment 92 days after iodination of the morphine. We assayed (a) morphine antibody kept at 4 #{176}C, with use of '25I-labeled morphine reagent kept at 4 #{176}C and at 37 #{176}C; (b) morphine antibody kept at 37 #{176}C, with use of '251-labeled reagent kept at 4 and 37 #{176}C; and (c) morphine antibody kept at 37 #{176}C, premixed with the '251-labeled morphine antigen.
The results are shown in Figure 9 . When the '251-labeled morphine was stored at 4 #{176}C and antibody at 4 or 37 #{176}C, a typical standard curve was obtained. However, storage of the '251-labeled morphine at 37 #{176}C and antibody at 4 or 37 #{176}C resulted in virtually no displacement of 1251-labeled morphine from antibody by the unlabeled morphine.
The higher initial counts under those conditions is probably due to the loss of antibody binding capacity by the '251-labeled morphine. Premixing the '251-labeled morphine with antibody and holding at 37 #{176}C in some way stabilizes the antigen, and a typical curve is obtained. With premixed reagents, the lower curve is invariably seen, and reflects the fact that with premixed reagents about 5 h of incubation is required to achieve the same displacement with unlabeled morphine as seen after a 1-h incubation when the '251-labeled morphine and morphine antibody are added in sequence.
Discussion
The Chloramine-T method of labeling proteins and peptides with iodine has been used extensively since the publications of Hunter and Greenwood (1) and Greenwood et al. (5) . By this procedure, radioiodine is coupled primarily to tyrosine at the optimum pH of 7.5 (6, 7, 8) . Indeed, Freedlender (8) reported that iodination at pH's above 7.5 result in iodination of groups other than tyrosine.
Because morphine and dihydromorphine contain a phenolic hydroxyl group, we investigated the possibility of iodinating these compounds by using the Chloramine-T method. The iodination, however, was performed at approximately pH 8.4 and might therefore be expected to result in labeling at a site other than on the phenolic ring. Because the labeling of dihydromorphine resulted in a product similar to that of iodinated morphine (Figures 1 and 3) , it is clear that iodination does not depend on the unsaturated bond between carbons 7 and 8 of morphine. However, the iodinated haptens produced during the labeling of morphine and dihydromorphine differed from each other, indicating that the double bond does play some role in the formation of '251-labeled morphine. Due to the fact that the iodinated products of interest were produced only by iodination with radioactive iodine (compare Figures 1 and 2 ), we postulate a radiolytic process. It seems likely that radiolysis occurs during the oxidative step of iodination. Physico-chemical characterization of 1251-labeled morphine was not pursued, owing to the hazards involved in vaporizing and hydrolyzing millicune amounts of iodide-125.
Experiments were designed to rule out the possibility that the radiolytic products of morphine and dihydromorphine are formed in some nonspecific manner. These experiments involved eliminating normal human plasma employed as a "protective" agent during elution from Bio-Gel P-2. As shown in Figure 5 , the formation and ultimate isolation of 1251-labeled morphine does not depend on the presence of normal human plasma. The unlikely possibility that 1251-labeled products were formed as a result of reactions between 125-iodine and Chloramine-T was also ruled out ( Figure 6 ).
The molar ratio of morphine to Na'251 routinely used for labeling was 70:1 and resulted in approximately 0.6 Ci/100 Ci of the radioactivity appearing as '251-labeled morphine. Assuming that 1251 binds to morphine on a 1:1 basis, only 1.2 g/100 g of the morphine present could theoretically be expected to carry one 1251atom. It appears, therefore, that about half of the morphine that could have been labeled was in fact labeled.
To increase the labeling efficiency, we used equimolar amounts of Na'251, Chloramine-T, and morphine in the iodination reaction. Where 95% of the iodinated product binds with antimorphine antibody when an excess of morphine is added to the reaction mixture (Figure 1) , only 45% of the product formed during equimolar iodination reacts with antibody.
Possibly the excess of Chloramine-T used in the standard iodination reaction alters the morphine molecule so as to permit greater binding to antibody, but this does not explain the chromatographic differences between the radiolabeled and nonradiolabeled products. More likely a combination of oxidation and radioactive iodinatiou is required for the iodine-labeled product to form.
Chromatography on DEAE-cellulose clearly shows that an '251-component freeof antibody-binding activity is dissociable from the '251-labeled morphine product. Although the chemical nature of this component was not studied, the results indicate that the percentage of 1251 released increases with time. It would be of interest to study the rate of release of this component in relation to the increased stability of '251-labeled morphine pre-mixed with antibody ( Figure 9) . Radioiodinated morphine and dihydromorphine both react readily with antibody produced in goats against 3-0-carboxymethyl morphine, indicating that the iodinated products retain the haptenic site. Figure 9 shows the relatively rapid loss of antibody binding activity by free 1251-labeled morphine at increased temperatures as compared to that of the product pre-mixed with antibody. This stabilization probably implies either a change in stenic configuration of the hapten or a neutralization of charge. It is known that the combination of antibody with antigen may result in release of water molecules from the surface of the combining site as well as from the surface of hydrophilic charged groups (9). Because antigenantibody complexes generally dissociate at high salt concentrations (10) and low pH's (11), it is evident that at least the primary binding is electrostatic. Whether or not these various factors influence the stability of the 1251-labeled morphine is unknown.
